标题：吉西他滨联合奈达铂治疗晚期肺鳞癌34例疗效观察

      作者：舒诚荣，曹爱玲
    (咸宁市中心医院肿瘤科，湖北 咸宁 437100)

      卷次： 2014年25卷13期

      【摘要】 目的 探讨吉西他滨联合奈达铂在晚期肺鳞癌中的临床应用效果。方法 选取 2011年 8月至
2012年11月我院收治的68例晚期肺鳞癌患者，随机分为吉西他滨联合奈达铂组(观察组)和吉西他滨联合顺铂组
(对照组)，每组各34例，比较两组患者治疗疗效、毒副反应、生存率和中位生存期。结果 两组患者均顺利完成
治疗，观察组有效率(44.1%)虽然高于对照组(35.2%)，但差异无统计学意义(P>0.05)；两组的毒副反应主要表现为
骨髓抑制，其次是胃肠道反应，且观察组Ⅰ级和Ⅱ级不良反应的发生率明显低于对照组(P<0.05)。Ⅲ级和Ⅳ级不
良反应也低于对照组(P<0.05)，两组均未发现有严重肝功能损害和周围神经的毒性损害。结论 西他滨联合奈
达铂治疗晚期肺鳞癌疗效肯定，且毒副反应轻，耐受性好，值得临床推广。

      【关键词】 吉西他滨；奈达铂；晚期肺鳞癌

      【中图分类号】 R734.2 【文献标识码】 A 【文章编号】 1003—6350（2014）13—1970—03


Clinical observation on the effect of gemcitabine combined with nedaplatin in the treatment of 34 patients with
advanced squamous cell lung cancer.
SHU Cheng-rong, CAO Ai-ling. Department of Oncology, Xianning Cental
Hospital, Xianning 437100, Hubei, CHINA

【Abstract】 Objective To explore the clinic application effect of gemcitabine combined with nedaplatin in
advanced squamous cell lung cancer. Methods From August 2011 to November 2012, 68 patients with advanced
squamous cell lung cancer from our hospital were enrolled in this study, which were randomly divided into gemcitabi-
ne combined with nedaplatin group (observation goup) and gemcitabine plus cisplatin group (control group). There
were 34 cases in each group. Treatment efficacy, side-effect, survival rate and the median survival period were com-
pared between the two groups. Results Patients from the two groups all successfully completed treatment. The effec-
tive rate of observation group was higher than of control group (44.1% versus 35.2%), but the difference was not statis-
tically significant (P>0.05). The main toxicity of two groups was bone marrow suppression, followed by gastrointesti-
nal reaction. In observation group, the incidence of grade I and gradeⅡ adverse reaction was significantly lower than
in control group (P<0.05). The incidence of gradeⅢ and gradeⅣ adverse reaction in observation group was also be-
low that in control group (P<0.05). There was no severe injury in liver function and peripheral nerve toxic damage in
two groups. Conclusion Curative effect of gemcitabine combined with nedaplatin in the treatment of advanced lung
carcinoma is positive with light toxicity reaction and good tolerability, so it is worthy of clinical promotion.

      【Key words】 Gemcitabine; Nedaplatin; Advanced squamous cell lung carcinoma
·临床经验·doi:10.3969/j.issn.1003-6350.2014.13.0763